Pfizer's High-Profile Strategy Chief Andrew Baum Exits After 6 Months, Role Eliminated

Pfizer's strategic pivot has hit a sudden reset. Andrew Baum, the former Citi investment banker brought in just six months ago to overhaul the pharmaceutical giant's post-pandemic direction, has abruptly departed his roles as Executive Vice President and Chief Strategy and Innovation Officer. His exit, confirmed by the company, signals a swift and significant reversal of a high-stakes leadership bet made in June 2024.

Baum was hired to redirect Pfizer's strategy following its windfall from COVID-19 products, tasked with charting a new course for innovation and growth. The company and sources framed his departure as a mutual decision, citing both the completion of his initial mandate and a broader operational streamlining effort. Pfizer stated the move is part of regular evaluations to 'position Pfizer to move faster, make clearer decisions, and advance innovation.' Baum will remain as an adviser to CEO Albert Bourla only until year-end, indicating a clean break is imminent.

The rapid turnover of a key architect for Pfizer's future raises immediate questions about the stability and clarity of its long-term strategic vision. Eliminating the chief strategy officer role suggests a recentralization of decision-making power at the top, potentially under Bourla himself. This move places intense scrutiny on the executive team to demonstrate that the promised operational streamlining will translate into tangible pipeline progress and market confidence, without the dedicated strategist hired to lead that very charge.